Viral determinants in the NS3 helicase and 2K peptide that promote West Nile virus resistance to antiviral action of 2′,5′-oligoadenylate synthetase 1b

Virology

Volumn 399, Issue 1, 2010, Pages 176-185

  Mertens, Eva ^a   Kajaste Rudnitski, Anna ^a   Torres, Shessy ^b   Funk, Anneke ^b   Frenkiel, Marie Pascale ^a   Iteman, Isabelle ^a   Khromykh, Alexander A ^b   Desprès, Philippe ^a  

^a INSTITUT PASTEUR   (France)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

2 ,5 oligoadenylate synthetases; Flavivirus 2K peptide; Flavivirus NS3 helicase; Innate immunity; Viral evasion; West Nile virus

Indexed keywords

2',5' OLIGOADENYLATE SYNTHETASE; 2',5' OLIGOADENYLATE SYNTHETASE 1B; 2K PEPTIDE; ADENOSINE TRIPHOSPHATASE; COMPLEMENTARY DNA; HELICASE; NONSTRUCTURAL PROTEIN 3; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS RNA;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; GENE MUTATION; MOLECULAR CLONING; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; VIRUS CELL INTERACTION; VIRUS INFECTION; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS STRAIN; WEST NILE FLAVIVIRUS;

2',5'-OLIGOADENYLATE SYNTHETASE; AMINO ACID SUBSTITUTION; ANIMALS; DISEASE SUSCEPTIBILITY; DNA HELICASES; GENE EXPRESSION REGULATION, VIRAL; MICE; POINT MUTATION; RNA, VIRAL; VIRUS REPLICATION; WEST NILE FEVER; WEST NILE VIRUS;

FLAVIVIRUS; WEST NILE VIRUS;

EID: 77249129709     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2009.12.036     Document Type: Article

References (47)

1. Artsob H., Gubler D.J., Enria D.A., Morales M.A., Pupo M., Bunning M.L., and Dudley J.P. West Nile virus in the New World: trends in the spread and proliferation of West Nile virus in the Western Hemisphere. Zoonoses Public Health 56 (2009) 357-369
2. Ashour J., Laurent-Rolle M., Shi P.Y., and García-Sastre A. NS5 of dengue virus mediates STAT2 binding and degradation. J. Virol. 83 (2009) 5408-5418
3. Beasley D.W.C., Whiteman M.C., Zhang S., Huang C.Y.-H., Schneider B.S., Smith D.R., Gromowski G.D., Higgs S., Kinney R.M., and Barrett A.D.T. Envelope protein glycosylation status influences mouse neuroinvasion phenotype of genetic lineage 1 West Nile virus strains. J. Virol. 79 (2005) 8339-8347
4. Brault A., Huang C., Langevin S., Kinney R., Bowen R., Ramey W., Panella N., Holmes E., Powers A., and Miller B. A single positively selected West Nile viral mutation confers increased virogenesis in American crows. Nat. Genet. 39 (2007) 1162-1166
5. Brinton M. The molecular biology of West Nile virus: a new invader of the Western Hemisphere. Annu. Rev. Microbiol. 56 (2002) 371-402
6. Butrapet S., Huang C.Y., Pierro D.J., Bhamarapravati N., Gubler D.J., and Kinney R.M. Attenuation markers of a candidate dengue type 2 vaccine virus, strain 16681 (PDK-53), are defined by mutations in the 5′ noncoding region and nonstructural proteins 1 and 3. J. Virol. 74 (2000) 3011-3019
7. Chambers T., Droll D., Walton A., Schwartz J., Wold W., and Nickells J. West Nile 25A virus infection of B-cell-deficient (MT) mice: characterization of neuroinvasiveness and pseudoreversion of the viral envelope protein. J. Gen. Virol. 89 (2008) 627-635
8. Charrel R.N., Brault A.C., Gallian P., Lemasson J.-J., Murgue B., Murri S., Pastorino B., Zeller H., de Chesse R., de Micco P., and de Lamballerie X. Evolutionary relationship between Old World West Nile virus strains. Evidence for viral gene flow between Africa, the Middle East, and Europe. Virology 315 (2003) 381-388
9. Davis C., Beasley D., Guzman H., Siirin M., Parsons R., Tesh R., and Barrett A. Emergence of attenuated West Nile virus variants in Texas, 2003. Virology 330 (2004) 342-350
10. Davis L.E., DeBiasi R., Goade D.E., Haaland K.Y., Harrington J.A., Harnar J.B., Pergam S.A., King M.K., DeMasters B.K., and Tyler K.L. West Nile virus neuroinvasive disease. Ann. Neurol. 60 (2006) 286-300
11. Despres P., Frenkiel M.-P., and Deubel V. Differences between cell membrane fusion activities of two dengue type-1 isolates reflect modifications of viral structure. Virology 196 (1993) 209-219
12. Diamond M., and Madhani H. Virus and host determinants of West Nile virus pathogenesis. PLoS Pathogens 5 (2009) e1000452
13. Feito M.J., Gómez-Gutiérrez J., Ayora S., Alonso J.C., Peterson D., and Gavilanes F. Insights into the oligomerization state-helicase activity relationship of West Nile virus NS3 NTPase/helicase. Virus Res. 135 (2008) 166-174
14. Frick D.N. The hepatitis C virus NS3 protein: a model RNA helicase and potential drug target. Curr. Issues Mol. Biol. 9 (2007) 1-20
15. Gubler D.J. Emerging infections: the continuing spread of West Nile virus in the Western Hemisphere. Clin. Infect. Dis. 45 (2007) 1039-1046
16. Hayes E.B., Sejvar J.J., Zaki S.R., Lanciotti R.S., Bode A.V., and Campbell G.L. Virology, pathology, and clinical manifestations of West Nile virus disease. Emerging Infect. Dis. 11 (2005) 1174-1179
17. Kajaste-Rudnitski A., Mashimo T., Frenkiel M.-P., Guénet J.-L., Lucas M., and Desprès P. The 2′,5′-oligoadenylate synthetase 1b is a potent inhibitor of West Nile virus replication inside infected cells. J. Biol. Chem. 281 (2005) 4624-4637
18. Lanciotti R., Ebel G.D., Deubel V., Kerst A.J., Murri S., Meyers R., Bowen M., McKinney N., Morril W.E., Crabtree M.B., Kramer L.D., and Roehrig J.T. Complete genome sequences and phylogenetic analysis of west nile virus strains isolated from the United States, Europe, and the Middle East. Virology 298 (2002) 96-105
19. Lee E., Hall R.A., and Lobigs M. Common E protein determinants for attenuation of glycosaminoglycan-binding variants of Japanese encephalitis and West Nile viruses. J. Virol. 78 (2004) 8271-8280
20. Lescar J., Luo D., Xu T., Sampath A., Lim S.P., Canard B., and Vasudevan S.G. Towards the design of antiviral inhibitors against flaviviruses: the case for the multifunctional NS3 protein from dengue virus as a target. Antivir. Res. 80 (2008) 94-101
21. Lim J., Lisco A., Mcdermott D., Huynh L., Ward J., Johnson B., Johnson H., Pape J., Foster G., Krysztof D., Follmann D., Stramer S., Margolis L., Murphy P., and Rice C. Genetic variation in OAS1 is a risk factor for initial infection with West Nile virus in man. PLoS Pathogens. 5 (2009) e1000321
22. Lin C., Amberg S.M., Chambers T.J., and Rice C.M. Cleavage at a novel site in the NS4A region by the yellow fever virus NS2B-3 proteinase is a prerequisite for processing at the downstream 4A/4B signalase site. J. Virol. 67 (1993) 2327-2335
23. Lindenbach B., Thiel H.J., and Rice C.M. Flaviviridae: the viruses ad their replication. In: Knipe D.M., and Howley P.M. (Eds). "Fields Virology". 5th ed 1 (2007), Lippincott Williams and Wilkins, Philadelphia 1101-1152
24. Liu W.J., Wang X.J., Mokhonov V.V., Shi P.-Y., Randall R., and Khromykh A.A. Inhibition of interferon signaling by the New York 99 strain and Kunjin subtype of West Nile virus involves blockage of STAT1 and STAT2 activation by nonstructural proteins. J. Virol. 79 (2005) 1934-1942
25. - ΔΔCT method. Methods 25 (2001) 402-408
26. Lucas M., Mashimo T., Frenkiel M.-P., Simon-Chazottes D., Montagutelli X., Ceccaldi P.-E., Guénet J.-L., and Desprès P. Infection of mouse neurones by West Nile virus is modulated by the interferon-inducible 2′-5′ oligoadenylate synthetase 1b protein. Immunol. Cell Biol. 81 (2003) 230-236
27. Lucas M., Frenkiel M., Mashimo T., Guénet J., Deubel V., Desprès P., and Ceccaldi P. The Israeli strain IS-98-ST1 of West Nile virus as viral model for West Nile encephalitis in the Old World. Virol. J. 1 (2004) 9
28. Mancini E., Assenberg R., Verma A., Walter T., Tuma R., Grimes J., Owens R., and Stuart D. Structure of the Murray Valley encephalitis virus RNA helicase at 1.9 A resolution. Protein Sci. 16 (2007) 2294-2300
29. Mashimo T., Lucas M., Simon-Chazottes D., Frenkiel M., Montagutelli X., Ceccaldi P., Deubel V., Guenet J.L., and Despres P. A nonsense mutation in the gene encoding 2′-5′-oligoadenylate synthetase/L1 isoform is associated with West Nile virus susceptibility in laboratory mice. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 11311-11316
30. Mashimo T., Lucas M., Simon-Chazottes D., Frenkiel M.-P., Montagutelli X., Ceccaldi P.-E., Deubel V., Guenet J.-L., and Despres P. A nonsense mutation in the gene encoding 2′-5′-oligoadenylate synthetase/L1 isoform is associated with West Nile virus susceptibility in laboratory mice. Proc. Natl. Acad. Sci. U.S.A. 99 17 (2002) 11311-11316
31. Mazzon M., Jones M., Davidson A., Chain B., and Jacobs M. Dengue virus NS5 inhibits interferon-alpha signaling by blocking signal transducer and activator of transcription 2 phosphorylation. J. Infect. Dis. 200 (2009) 1261-1270
32. Miller S., Kastner S., Krijnse-Locker J., Buhler S., and Bartenschlager R. The non-structural protein 4A of dengue virus is an integral membrane protein inducing membrane alterations in a 2K-regulated manner. J. Biol. Chem. 282 (2007) 8873-8882
33. Muñoz-Jordán J.L., Laurent-Rolle M., Ashour J., Martínez-Sobrido L., Ashok M., Lipkin W.I., and García-Sastre A. Inhibition of alpha/beta interferon signaling by the NS4B protein of flaviviruses. J. Virol. 79 (2005) 8004-8013
34. Perelygin A., Scherbik S.V., Zhulin I.B., Stockman B.M., Li Y., and Brinton M.A. Positional cloning of the murine flavivirus resistance gene. Proc. Natl. Acad. Sci. 99 (2002) 9322-9327
35. Roosendaal J., Westaway E.G., Khromykh A., and Mackenzie J.M. Regulated cleavages at the West Nile virus NS4A-2K-NS4B junctions play a major role in rearranging cytoplasmic membranes and Golgi trafficking of the NS4A protein. J. Virol. 80 (2006) 4623-4632
36. Samuel C.E. Host genetic variability and West Nile virus susceptibility. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 11555-11557
37. Samuel M., and Diamond M.S. Pathogenesis of West Nile virus infection: a balance between virulence, innate and adaptive immunity, and viral evasion. J. Virol. 80 (2006) 9349-9360
38. Shiryaev S., Chernov A., Aleshin A., Shiryaeva T., and Strongin A. NS4A regulates the ATPase activity of the NS3 helicase: a novel co-factor role of the non-structural protein NS4A from West Nile virus. J. Gen. Virol. 90 (2009) 2081-2085
39. Sikora B., Chen Y., Lichti C.F., Harrison M.K., Jennings T.A., Tang Y., Tackett A.J., Jordan J.B., Sakon J., Cameron C.E., and Raney K.D. Hepatitis C virus NS3 helicase forms oligomeric structures that exhibit optimal DNA unwinding activity in vitro. J. Biol. Chem. 283 17 (2008) 11516-11525
40. Silverman R.H. Viral Encounters with 2′,5′-oligoadenylate synthetase and RNase L during the interferon antiviral response. J. Virol. 81 (2007) 12720-12729
41. Suthar M., Gale Jr. M., and Owen D. Evasion and disruption of innate immune signalling by hepatitis C and West Nile viruses. Cell. Microbiol. 11 (2009) 880-888
42. Tatsumi R., Sekiya S., Nakanishi R., Mizutani M., Kojima S.-I., and Sokawa Y. Function of ubiquitin-like domain of chicken 2′-5′-oligoadenylate synthetase in conformational stability. J. Interferon Cytokine Res. 23 (2003) 667-676
43. Umareddy I., Chao A., Sampath A., Gu F., and Vasudevan S.G. Dengue virus NS4B interacts with NS3 and dissociates it from single-stranded RNA. J. Gen. Virol. 87 (2006) 2605-2614
44. Yamamoto A., Iwata A., Koh Y., Kawai S., Murayama S., Hamada K., Maekawa S., Ueda S., and Sokawa Y. Two types of chicken 2′,5′-oligoadenylate synthetase mRNA derived from alleles at a single locus. Biochim. Biophys. Acta 1395 (1998) 181-191
45. Zhou A., Paranjape J., Brown T.L., Nie H., Naik S., Dong B., Chang A., Trapp B., Fairchild R., Colmenares C., and Silverman R.H. Interferon action and apoptosis are defective in mice devoid of 2′,5′-oligoadenylate-dependent RNase L. EMBO J. 16 (1997) 6355-6363
46. Zou G., Puigbasagoiti F., Zhang B., Qing M., Chen L., Pankiewicz K., Felczak K., Yuan Z., and Shi P. A single-amino acid substitution in West Nile virus 2K peptide between NS4A and NS4B confers resistance to lycorine, a flavivirus inhibitor. Virology 384 (2008) 242-252
47. Zou G., Zhang B., Lim P.-Y., Yuan Z., Bernard K.A., and Shi P.Y. Exclusion of West Nile virus superinfection through RNA replication. J. Virol. 83 (2009) 11765-11776